二甲双胍对糖耐量减低合并冠心病者冠状动脉介入术后的影响

Effect of metformin treatment on cardiovascular events and restenosis after coronary stenting in patients with impaired glucose tolerance accompanied by coronary heart disease

目的观察二甲双胍对糖耐量减低(IGT)合并冠心病患者行冠状动脉介入术后的影响。方法将IGT合并冠状动脉病变且接受冠状动脉介入术治疗的125例患者分为两组。治疗组64例,在常规治疗的基础上加用二甲双胍进行干预;对照组61例,仅予常规治疗。观察术后1年的心血管事件及支架内再狭窄的发生情况。结果术后1年110例患者获得随访,治疗组56例,对照组54例。治疗组心血管事件和支架内再狭窄发生率分别为14％(8／56例)和18％(10／56例),均明显低于对照组的22％(12／54例)和26％(14／54例,P值均<0．01)。结论在IGT合并冠心病并行冠状动脉介入术的患者中,应用二甲双胍进行干预,可以降低心血管事件及冠状动脉支架内再狭窄发生率。

Objective To study the effect of metformin treatment on cardiovascular events and restenosis after coronary stenting in patients with impaired glucose tolerance accompanied by coronary heart disease. Methods Patients with impaired glucose tolerance and coronary heart disease were randomized in two groups after coronary stenting, group A： received oral metformin on basis of standard CHD therapy, group B： only received standard therapy without metformin. Both groups were followed up for one year. Cardiovascular events and angiographic restenosis were evaluated at the end of follow-up. Results Cardiovascular events and restenosis after coronary stenting were significantly lower in group A than those in group B [14%（8/56） vs 22%（12/54）, P 〈 0.01; 18% （10/56） vs 26M（14/54）, P % 0. 011 respectively. Conclusion Metformin can decrease cardiovascular events and restenosis in patients with impaired glucose tolerance accompanied by coronary heart disease.